Intellia Therapeutics, Inc.
NTLA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$101,324 | -$101,255 | -$114,329 | -$128,898 |
| Dep. & Amort. | $4,936 | $2,474 | $2,498 | $2,566 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $19,604 | $22,036 | $21,840 | $39,617 |
| Change in WC | $4,409 | -$19,871 | -$58,784 | $2,040 |
| Other Non-Cash | -$4,524 | -$3,006 | -$155 | -$520 |
| Operating Cash Flow | -$76,899 | -$99,622 | -$148,930 | -$85,195 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$29 | -$239 | -$735 | -$981 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$116,651 | -$55,600 | -$83,209 | -$169,102 |
| Inv. Sales/Matur. | $115,939 | $162,749 | $178,272 | $321,648 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | -$741 | $106,910 | $94,328 | $151,565 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $114,760 | $13,415 | $0 | -$30 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $97 | $1,237 | $0 | $2,347 |
| Financing Cash Flow | $114,857 | $14,652 | $0 | $2,317 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $37,217 | $21,940 | -$54,602 | $68,687 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $170,125 | $148,185 | $202,787 | $134,100 |
| End Cash | $207,342 | $170,125 | $148,185 | $202,787 |
| Free Cash Flow | -$76,928 | -$99,861 | -$149,665 | -$86,176 |